Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months
BACKGROUND On-demand therapy may offer an effective approach to the long-term management of gastro-oesophageal reflux disease (GORD) without oesophagitis. AIM To examine the efficacy of the novel proton pump inhibitor esomeprazole as on-demand therapy in endoscopy-negative GORD. PATIENTS AND METHODS...
Gespeichert in:
| Veröffentlicht in: | European journal of gastroenterology & hepatology 2002-08, Vol.14 (8), p.857-863 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 863 |
|---|---|
| container_issue | 8 |
| container_start_page | 857 |
| container_title | European journal of gastroenterology & hepatology |
| container_volume | 14 |
| creator | Talley, Nicholas J Venables, Thomas L Green, Jonathan R. B Armstrong, David O'Kane, Kevin P. J Giaffer, Mustafa Bardhan, Karna D Carlsson, Rolf G. S Chen, Samuel Hasselgren, Göran S |
| description | BACKGROUND On-demand therapy may offer an effective approach to the long-term management of gastro-oesophageal reflux disease (GORD) without oesophagitis.
AIM To examine the efficacy of the novel proton pump inhibitor esomeprazole as on-demand therapy in endoscopy-negative GORD.
PATIENTS AND METHODS Endoscopy-negative GORD patients who achieved complete resolution of heartburn after short-term esomeprazole or omeprazole treatment (n = 721) were randomized to esomeprazole 20 mg (n = 282), 40 mg (n = 293) or placebo (n = 146) on demand (maximum one dose/day) for 6 months. The primary and secondary efficacy endpoints were time to study discontinuation due to (i) unwillingness to continue and (ii) inadequate control of heartburn, respectively.
RESULTS Both doses of esomeprazole were more effective than placebo. During the 6-month period, 42% of placebo recipients discontinued treatment due to unwillingness to continue, compared with 8% and 11% of esomeprazole 20 mg and 40 mg recipients, respectively. Overall, more patients treated with esomeprazole were free from gastrointestinal symptoms after 6 months of on-demand therapy.
CONCLUSIONS Esomeprazole 20 mg was superior to placebo for on-demand treatment of GORD; a higher dose did not confer additional clinical benefit. Over 90% of patients were willing to continue on-demand treatment with esomeprazole 20 mg over a 6-month period. |
| doi_str_mv | 10.1097/00042737-200208000-00008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71997208</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71997208</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3868-ec3907e3aa58234857b0730208fc09bb5add325d739143503443de2877497b9f3</originalsourceid><addsrcrecordid>eNp1kk2P1SAUhhujca6jf8Gcje5QKLQUd2YyfiSTuNHEXUPpaYtSqNDO9foX_VNy516dlQvCITzng_elKIDRV4wq-ZpSKkrJJSkpLWmTjyQv2jwodkxITqq6kQ-LHVWVILViXy-KJyl9o5RJzuTj4oKVTJaC1rvi93UKMy5R_woOQVCYR9C-h_IusglwGKzRxoYtgfWwTggu-JGsGGeYtdcjzuhXCAMserU5TLC36wTo-5BMWA7E45hvbhFGndYYSMAUliknagcRB7f9hN4m1AnfgIbFaYNdICb4DDuHPazRZjR3CJ70OB_ny3NEvRxgCBFqmDM7pafFo0G7hM_O-2Xx5d3156sP5ObT-49Xb2-I4U3dEDRcUYlc66opuWgq2VHJjzoOhqquq3Tf87LqJVdM8IpyIXiPZSOlULJTA78sXp7qLjH82DCt7WyTQee0xyxTK5lSMpfLYHMCTQwp5ae2S7SzjoeW0fZoZPvXyPafke2dkTn1-bnH1s3Y3yeencvAizOgk9FuiNobm-453lSqoixz4sTtg8uepe9u22Nspyz-OrX_-0j8D4Ctt9w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71997208</pqid></control><display><type>article</type><title>Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Talley, Nicholas J ; Venables, Thomas L ; Green, Jonathan R. B ; Armstrong, David ; O'Kane, Kevin P. J ; Giaffer, Mustafa ; Bardhan, Karna D ; Carlsson, Rolf G. S ; Chen, Samuel ; Hasselgren, Göran S</creator><creatorcontrib>Talley, Nicholas J ; Venables, Thomas L ; Green, Jonathan R. B ; Armstrong, David ; O'Kane, Kevin P. J ; Giaffer, Mustafa ; Bardhan, Karna D ; Carlsson, Rolf G. S ; Chen, Samuel ; Hasselgren, Göran S</creatorcontrib><description>BACKGROUND On-demand therapy may offer an effective approach to the long-term management of gastro-oesophageal reflux disease (GORD) without oesophagitis.
AIM To examine the efficacy of the novel proton pump inhibitor esomeprazole as on-demand therapy in endoscopy-negative GORD.
PATIENTS AND METHODS Endoscopy-negative GORD patients who achieved complete resolution of heartburn after short-term esomeprazole or omeprazole treatment (n = 721) were randomized to esomeprazole 20 mg (n = 282), 40 mg (n = 293) or placebo (n = 146) on demand (maximum one dose/day) for 6 months. The primary and secondary efficacy endpoints were time to study discontinuation due to (i) unwillingness to continue and (ii) inadequate control of heartburn, respectively.
RESULTS Both doses of esomeprazole were more effective than placebo. During the 6-month period, 42% of placebo recipients discontinued treatment due to unwillingness to continue, compared with 8% and 11% of esomeprazole 20 mg and 40 mg recipients, respectively. Overall, more patients treated with esomeprazole were free from gastrointestinal symptoms after 6 months of on-demand therapy.
CONCLUSIONS Esomeprazole 20 mg was superior to placebo for on-demand treatment of GORD; a higher dose did not confer additional clinical benefit. Over 90% of patients were willing to continue on-demand treatment with esomeprazole 20 mg over a 6-month period.</description><identifier>ISSN: 0954-691X</identifier><identifier>EISSN: 1473-5687</identifier><identifier>DOI: 10.1097/00042737-200208000-00008</identifier><identifier>PMID: 12172406</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins, Inc</publisher><subject>Administration, Oral ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Digestive system ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug Administration Schedule ; Esomeprazole ; Esophagoscopy ; Female ; Follow-Up Studies ; Gastroesophageal Reflux - diagnosis ; Gastroesophageal Reflux - drug therapy ; Gastroscopy ; Humans ; Long-Term Care ; Male ; Medical sciences ; Middle Aged ; Omeprazole - administration & dosage ; Patient Satisfaction ; Pharmacology. Drug treatments ; Probability ; Reference Values ; Severity of Illness Index ; Treatment Outcome</subject><ispartof>European journal of gastroenterology & hepatology, 2002-08, Vol.14 (8), p.857-863</ispartof><rights>2002 Lippincott Williams & Wilkins, Inc.</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3868-ec3907e3aa58234857b0730208fc09bb5add325d739143503443de2877497b9f3</citedby><cites>FETCH-LOGICAL-c3868-ec3907e3aa58234857b0730208fc09bb5add325d739143503443de2877497b9f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13859501$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12172406$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Talley, Nicholas J</creatorcontrib><creatorcontrib>Venables, Thomas L</creatorcontrib><creatorcontrib>Green, Jonathan R. B</creatorcontrib><creatorcontrib>Armstrong, David</creatorcontrib><creatorcontrib>O'Kane, Kevin P. J</creatorcontrib><creatorcontrib>Giaffer, Mustafa</creatorcontrib><creatorcontrib>Bardhan, Karna D</creatorcontrib><creatorcontrib>Carlsson, Rolf G. S</creatorcontrib><creatorcontrib>Chen, Samuel</creatorcontrib><creatorcontrib>Hasselgren, Göran S</creatorcontrib><title>Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months</title><title>European journal of gastroenterology & hepatology</title><addtitle>Eur J Gastroenterol Hepatol</addtitle><description>BACKGROUND On-demand therapy may offer an effective approach to the long-term management of gastro-oesophageal reflux disease (GORD) without oesophagitis.
AIM To examine the efficacy of the novel proton pump inhibitor esomeprazole as on-demand therapy in endoscopy-negative GORD.
PATIENTS AND METHODS Endoscopy-negative GORD patients who achieved complete resolution of heartburn after short-term esomeprazole or omeprazole treatment (n = 721) were randomized to esomeprazole 20 mg (n = 282), 40 mg (n = 293) or placebo (n = 146) on demand (maximum one dose/day) for 6 months. The primary and secondary efficacy endpoints were time to study discontinuation due to (i) unwillingness to continue and (ii) inadequate control of heartburn, respectively.
RESULTS Both doses of esomeprazole were more effective than placebo. During the 6-month period, 42% of placebo recipients discontinued treatment due to unwillingness to continue, compared with 8% and 11% of esomeprazole 20 mg and 40 mg recipients, respectively. Overall, more patients treated with esomeprazole were free from gastrointestinal symptoms after 6 months of on-demand therapy.
CONCLUSIONS Esomeprazole 20 mg was superior to placebo for on-demand treatment of GORD; a higher dose did not confer additional clinical benefit. Over 90% of patients were willing to continue on-demand treatment with esomeprazole 20 mg over a 6-month period.</description><subject>Administration, Oral</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Digestive system</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>Drug Administration Schedule</subject><subject>Esomeprazole</subject><subject>Esophagoscopy</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gastroesophageal Reflux - diagnosis</subject><subject>Gastroesophageal Reflux - drug therapy</subject><subject>Gastroscopy</subject><subject>Humans</subject><subject>Long-Term Care</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Omeprazole - administration & dosage</subject><subject>Patient Satisfaction</subject><subject>Pharmacology. Drug treatments</subject><subject>Probability</subject><subject>Reference Values</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><issn>0954-691X</issn><issn>1473-5687</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kk2P1SAUhhujca6jf8Gcje5QKLQUd2YyfiSTuNHEXUPpaYtSqNDO9foX_VNy516dlQvCITzng_elKIDRV4wq-ZpSKkrJJSkpLWmTjyQv2jwodkxITqq6kQ-LHVWVILViXy-KJyl9o5RJzuTj4oKVTJaC1rvi93UKMy5R_woOQVCYR9C-h_IusglwGKzRxoYtgfWwTggu-JGsGGeYtdcjzuhXCAMserU5TLC36wTo-5BMWA7E45hvbhFGndYYSMAUliknagcRB7f9hN4m1AnfgIbFaYNdICb4DDuHPazRZjR3CJ70OB_ny3NEvRxgCBFqmDM7pafFo0G7hM_O-2Xx5d3156sP5ObT-49Xb2-I4U3dEDRcUYlc66opuWgq2VHJjzoOhqquq3Tf87LqJVdM8IpyIXiPZSOlULJTA78sXp7qLjH82DCt7WyTQee0xyxTK5lSMpfLYHMCTQwp5ae2S7SzjoeW0fZoZPvXyPafke2dkTn1-bnH1s3Y3yeencvAizOgk9FuiNobm-453lSqoixz4sTtg8uepe9u22Nspyz-OrX_-0j8D4Ctt9w</recordid><startdate>200208</startdate><enddate>200208</enddate><creator>Talley, Nicholas J</creator><creator>Venables, Thomas L</creator><creator>Green, Jonathan R. B</creator><creator>Armstrong, David</creator><creator>O'Kane, Kevin P. J</creator><creator>Giaffer, Mustafa</creator><creator>Bardhan, Karna D</creator><creator>Carlsson, Rolf G. S</creator><creator>Chen, Samuel</creator><creator>Hasselgren, Göran S</creator><general>Lippincott Williams & Wilkins, Inc</general><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200208</creationdate><title>Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months</title><author>Talley, Nicholas J ; Venables, Thomas L ; Green, Jonathan R. B ; Armstrong, David ; O'Kane, Kevin P. J ; Giaffer, Mustafa ; Bardhan, Karna D ; Carlsson, Rolf G. S ; Chen, Samuel ; Hasselgren, Göran S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3868-ec3907e3aa58234857b0730208fc09bb5add325d739143503443de2877497b9f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Administration, Oral</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Digestive system</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>Drug Administration Schedule</topic><topic>Esomeprazole</topic><topic>Esophagoscopy</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gastroesophageal Reflux - diagnosis</topic><topic>Gastroesophageal Reflux - drug therapy</topic><topic>Gastroscopy</topic><topic>Humans</topic><topic>Long-Term Care</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Omeprazole - administration & dosage</topic><topic>Patient Satisfaction</topic><topic>Pharmacology. Drug treatments</topic><topic>Probability</topic><topic>Reference Values</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Talley, Nicholas J</creatorcontrib><creatorcontrib>Venables, Thomas L</creatorcontrib><creatorcontrib>Green, Jonathan R. B</creatorcontrib><creatorcontrib>Armstrong, David</creatorcontrib><creatorcontrib>O'Kane, Kevin P. J</creatorcontrib><creatorcontrib>Giaffer, Mustafa</creatorcontrib><creatorcontrib>Bardhan, Karna D</creatorcontrib><creatorcontrib>Carlsson, Rolf G. S</creatorcontrib><creatorcontrib>Chen, Samuel</creatorcontrib><creatorcontrib>Hasselgren, Göran S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of gastroenterology & hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Talley, Nicholas J</au><au>Venables, Thomas L</au><au>Green, Jonathan R. B</au><au>Armstrong, David</au><au>O'Kane, Kevin P. J</au><au>Giaffer, Mustafa</au><au>Bardhan, Karna D</au><au>Carlsson, Rolf G. S</au><au>Chen, Samuel</au><au>Hasselgren, Göran S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months</atitle><jtitle>European journal of gastroenterology & hepatology</jtitle><addtitle>Eur J Gastroenterol Hepatol</addtitle><date>2002-08</date><risdate>2002</risdate><volume>14</volume><issue>8</issue><spage>857</spage><epage>863</epage><pages>857-863</pages><issn>0954-691X</issn><eissn>1473-5687</eissn><abstract>BACKGROUND On-demand therapy may offer an effective approach to the long-term management of gastro-oesophageal reflux disease (GORD) without oesophagitis.
AIM To examine the efficacy of the novel proton pump inhibitor esomeprazole as on-demand therapy in endoscopy-negative GORD.
PATIENTS AND METHODS Endoscopy-negative GORD patients who achieved complete resolution of heartburn after short-term esomeprazole or omeprazole treatment (n = 721) were randomized to esomeprazole 20 mg (n = 282), 40 mg (n = 293) or placebo (n = 146) on demand (maximum one dose/day) for 6 months. The primary and secondary efficacy endpoints were time to study discontinuation due to (i) unwillingness to continue and (ii) inadequate control of heartburn, respectively.
RESULTS Both doses of esomeprazole were more effective than placebo. During the 6-month period, 42% of placebo recipients discontinued treatment due to unwillingness to continue, compared with 8% and 11% of esomeprazole 20 mg and 40 mg recipients, respectively. Overall, more patients treated with esomeprazole were free from gastrointestinal symptoms after 6 months of on-demand therapy.
CONCLUSIONS Esomeprazole 20 mg was superior to placebo for on-demand treatment of GORD; a higher dose did not confer additional clinical benefit. Over 90% of patients were willing to continue on-demand treatment with esomeprazole 20 mg over a 6-month period.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins, Inc</pub><pmid>12172406</pmid><doi>10.1097/00042737-200208000-00008</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0954-691X |
| ispartof | European journal of gastroenterology & hepatology, 2002-08, Vol.14 (8), p.857-863 |
| issn | 0954-691X 1473-5687 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71997208 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Administration, Oral Adolescent Adult Aged Aged, 80 and over Biological and medical sciences Digestive system Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Esomeprazole Esophagoscopy Female Follow-Up Studies Gastroesophageal Reflux - diagnosis Gastroesophageal Reflux - drug therapy Gastroscopy Humans Long-Term Care Male Medical sciences Middle Aged Omeprazole - administration & dosage Patient Satisfaction Pharmacology. Drug treatments Probability Reference Values Severity of Illness Index Treatment Outcome |
| title | Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T04%3A10%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Esomeprazole%2040%20mg%20and%2020%20mg%20is%20efficacious%20in%20the%20long-term%20management%20of%20patients%20with%20endoscopy-negative%20gastro-oesophageal%20reflux%20disease:%20a%20placebo-controlled%20trial%20of%20on-demand%20therapy%20for%206%20months&rft.jtitle=European%20journal%20of%20gastroenterology%20&%20hepatology&rft.au=Talley,%20Nicholas%20J&rft.date=2002-08&rft.volume=14&rft.issue=8&rft.spage=857&rft.epage=863&rft.pages=857-863&rft.issn=0954-691X&rft.eissn=1473-5687&rft_id=info:doi/10.1097/00042737-200208000-00008&rft_dat=%3Cproquest_cross%3E71997208%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71997208&rft_id=info:pmid/12172406&rfr_iscdi=true |